AUG 24, 2020 11:30 AM PDT

FDA Grants Emergency Approval for Blood Plasma to Treat COVID-19

WRITTEN BY: Annie Lennon

The US Food and Drug Agency (FDA) has given emergency approval for expanded use of antibody-rich blood plasma to help those hospitalized with COVID-19. While President Donald Trump remains highly optimistic about the treatment, others remain skeptical of its effectiveness. 

Nevertheless, the decision will broaden the usage of the treatment, already administered to over 70,000 patients. Unlike a new drug, however, blood plasma cannot be manufactured in millions of doses- its availability is dependent on blood donations. As such, President Trump has urged people who have recovered from the virus to donate their blood via a nationwide campaign organized to collect it. 

Despite some optimism around the treatment, some warn that no randomized trials have confirmed its efficacy. Regardless, from data collected so far from over a dozen studies, the FDA says that it is ‘reasonable to believe that the treatment may be effective in lessening the severity or shortening the length of COVID-19 illness in some hospitlized patients’, should they receive it early enough. 

According to Dr. Peter Marks, a director at the FDA, patients who received plasma with a high level of antibodies within three days of being diagnosed, and provided they were not on a respirator, were 35% more likely to be alive a month after the treatment than those who received plasma with a low level of antibodies. This was only true for patients under 80 years old, however. 

Meanwhile, health authorities around the world remain uncertain about the treatment and its efficacy. The World Health Organization, for example, says that it is still ‘experimental’ and that the evidence base is so far too small to report meaningful results. In the same vein, Jonathan Reiner, a professor of medicine at George Washington University, called approval of the treatment a ‘political stunt’. 

Sources: New York TimesBBC

About the Author
  • Science writer with a keen interest in behavioral biology, consciousness medicine and technology. Her current focus is how the interplay of these fields can create meaningful interactions, products and environments.
You May Also Like
MAR 04, 2021
Drug Discovery & Development
How Placebo Drugs for Pain Work in the Brain
MAR 04, 2021
How Placebo Drugs for Pain Work in the Brain
Researchers from Dartmouth College have found that pain relief drugs that work via the placebo effect reduce pain-relate ...
MAR 18, 2021
Drug Discovery & Development
New Cancer Immunotherapy Targets Genetic Alteration in All Cancers
MAR 18, 2021
New Cancer Immunotherapy Targets Genetic Alteration in All Cancers
Researchers have developed a prototype for a new kind of cancer immunotherapy. The therapy uses engineered T-cells to ta ...
MAR 18, 2021
Technology
Technology Fixes Errors Associated with Self-Administering Medications
MAR 18, 2021
Technology Fixes Errors Associated with Self-Administering Medications
Almost all medications allow patients to self-administer—however, that does not mean that they always get it right ...
APR 01, 2021
Microbiology
Mapping the Wild Microbiome to Search for Therapeutic Agents
APR 01, 2021
Mapping the Wild Microbiome to Search for Therapeutic Agents
Many people think of bacteria as disgusting germs, but there are plenty of important bacterial species that provide us w ...
APR 07, 2021
Drug Discovery & Development
Therapeutics Enhance The Body's Natural Killers
APR 07, 2021
Therapeutics Enhance The Body's Natural Killers
Most people who have been prescribed pain killers are familiar with fentanyl, oxycodone, and morphine. These substances ...
MAY 03, 2021
Drug Discovery & Development
Low Dose Radiation May Improve Symptoms of Alzheimer's
MAY 03, 2021
Low Dose Radiation May Improve Symptoms of Alzheimer's
While high doses of radiation are known to be harmful, low doses may be able to help the body protect and repair. And no ...
Loading Comments...